OncoMatch

OncoMatch/Clinical Trials/NCT06162650

Total Neoadjuvant Therapy in Rectal Cancer

Is NCT06162650 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies mFOLFOX6 for rectal cancer.

Phase 2RecruitingNational Cheng-Kung University HospitalNCT06162650Data as of Jun 2026Location: Taiwan

Treatment: mFOLFOX6In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated. Patients with stage II or III middle/low rectal cancer will be prospective enrolled. The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered. The primary endpoint is the complete response (CR) rate which will take into account the patients with clinical and pathological complete response.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

mFOLFOX6

Cancer type

Colorectal Cancer

Disease stage

Required: Stage II, III

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≥ 20

Prior therapy

No prior treatment (treatment-naive required)
Max 0 prior lines

Cannot have received: chemotherapy

No prior chemotherapy, radiotherapy or surgery for rectal cancer

Cannot have received: radiotherapy

No prior chemotherapy, radiotherapy or surgery for rectal cancer

Cannot have received: surgery

No prior chemotherapy, radiotherapy or surgery for rectal cancer

Cannot have received: pelvic radiotherapy

Patients who have received prior pelvic radiotherapy

Lab requirements

Blood counts

anc ≥1,500/μl; hb ≥8.0 gm/dl; platelet 100,000/mm3

Kidney function

creatinine ≤1.5x upper normal limit

Liver function

total bilirubin ≤1.5x upper normal limit; ast ≤3x upper normal limit; alt ≤3x upper normal limit

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT06162650 currently recruiting?

Yes, this trial is currently recruiting patients.

Can patients have received prior systemic therapy?

No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.

What disease stage is eligible?

Stage II or III is required.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify